MWPCG
XPH icon

Measured Wealth Private Client Group’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Measured Wealth Private Client Group’s Portfolio XPH Stock Details XPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.53M Buy
+68,306
New +$4M 1.09% 24

Other funds holding XPH

Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
Envestnet Portfolio Solutions
Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
EPGL
Evelyn Partners Group Ltd London $46.9B AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return

Measured Wealth Private Client Group's XPH Position: Q2 2026 in Review

Measured Wealth Private Client Group opened a new position in State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2026: 68,306 shares worth $4.53M. The stake represents 1.09% of the portfolio and ranks #24 among its holdings.

47 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

  • Measured Wealth Private Client Group held 68,306 shares of State Street SPDR S&P Pharmaceuticals ETF worth $4.53M as of Q2 2026.
  • State Street SPDR S&P Pharmaceuticals ETF was a new Measured Wealth Private Client Group position in Q2 2026.
  • State Street SPDR S&P Pharmaceuticals ETF made up 1.09% of Measured Wealth Private Client Group's portfolio in Q2 2026, its #24 holding.
  • 47 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on Measured Wealth Private Client Group's 13F filing for Q2 2026, filed 10 Aug 2026.